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Abstract 
Background 
Sepsis is a leading cause of childhood mortality worldwide. We assessed population-based 
incidence and outcomes of blood culture-proven bacterial sepsis in children in Switzerland. 
Methods 
Multicenter national prospective cohort study including neonates and children <17 years with 
blood culture-proven bacterial sepsis from September 1, 2011, to December 31, 2015. Ten 
pediatric hospitals, including all five pediatric university hospitals, participated in the study. 
Children were eligible if they met criteria for systemic inflammatory response syndrome, as 
defined by 2005 pediatric consensus definition, at the time of blood culture sampling. Incidence 
was calculated by dividing the number of annual sepsis episodes in the study for the years 2012 
to 2015 by the end of year resident pediatric population in Switzerland. The primary outcome 
was in-hospital mortality in the first 30 days after sepsis onset. 
Findings 
Of 1181 blood culture-proven bacterial sepsis episodes, 382 (32%) occurred in previously healthy 
children, 402 (34%) in neonates, and 397 (34%) in children with comorbidities. The incidence 
was 25·1/100'000 in children (95%-CI 23·8-26·4), and 146·0/100'000 in neonates (133·2-159·6). 
Central line-associated bloodstream infection and primary bloodstream infection accounted for 
48% (569/1181) of episodes. The case fatality ratio (CFR) was 7% and was higher in neonates 
(11%, adjusted OR 4·41, 1·75-11·1) and children with comorbidities (7%, OR 4·97, 1·84-13·4) 
compared to previously healthy children (3%). The CFR was 1% in 726/1181 (61%) episodes 
without organ dysfunction and increased to 17% in 455/1181 (39%) episodes where an organ 
dysfunction was present (adjusted OR 4·84, 1·40-16·7). 
Interpretation 
The burden of blood culture-proven bacterial sepsis on child health remains considerable. We 
observed key differences in predominant organisms, severity, and outcome between neonates, 
previously healthy children and those with comorbidities. While the majority of blood culture-
proven bacterial sepsis had no organ dysfunction, presence and number of organ dysfunctions 
were strongly associated with mortality. 
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Introduction 
Invasive bacterial infections represent one of the leading causes of childhood mortality 
worldwide.
1
 Neonates and young children are particularly susceptible to severe or lethal 
infections.
2
 Recent studies from the United States reported that the incidence of severe sepsis in 
children increased from 0·56 to 0·89 cases per 1,000 children over the past decade.
3,4
 In adults, 
bloodstream infections rank among the top seven causes of death in the US and Western Europe.
5 
The incidence of bloodstream infections is highest at the extremes of age, in neonates and the 
elderly,
6
 yet there is a lack of comprehensive population-based analyses on severe bacterial 
infections in childhood. In addition to age, host factors such as underlying disease are primary 
determinants of susceptibility and outcomes.
7,8
 Importantly, epidemiology of invasive infections 
is subject to change as a result of vaccination campaigns,
9
 and the increasing number of patients 
at risk of acquiring healthcare-associated infections including premature newborns, children with 
malignancies or after transplantation.
10
 Considering the detrimental effect of delays in 
antimicrobial treatment in bacterial sepsis,
11
 representative data on the contemporary burden of 
bacterial sepsis are key to guide national strategies for optimal antibiotic usage.
12
Sepsis in adults was recently re-defined as a life-threatening organ dysfunction resulting from a 
dysregulated host response to infection.
13
 In contrast, the pediatric definition of sepsis is still 
based on the 2005 consensus
2
 requiring the presence of systemic inflammatory response 
syndrome (SIRS) in patients with suspected infection, which have been criticized for lack of 
specificity to identify patients subgroups with substantially higher mortality.
14
 A limitation of 
larger studies on childhood sepsis consists in the use of clinical definitions of sepsis, with only a 
minority of sepsis episodes being microbiologically confirmed, and the lack of robust 
characterization of the presence and impact of organ dysfunction on outcomes.
3,4
This population-based national prospective cohort study aimed to describe the epidemiology and 
severity of blood culture-proven bacterial sepsis, as defined by the 2005 consensus definitions,
2 
in children in Switzerland. We investigated patterns of blood culture-proven bacterial sepsis in 
relation to incidence, pathogens, severity, organ dysfunctions, and outcomes. 
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Methods 
Study design 
The Swiss Pediatric Sepsis Study
15
 is a prospective national observational multicenter cohort 
study investigating blood culture-proven bacterial sepsis in children in Switzerland from 
September 1, 2011, to December 31, 2015. All ten major children’s hospitals in the country 
participated in the study, including all five pediatric University hospitals, and the five largest 
regional pediatric hospitals. During the study, these centers accounted for 78% of all hospital 
admissions, and 98% of all pediatric intensive care unit (PICU) admissions with an International 
Classification of Diseases (ICD)-10 code for pathogen-specific sepsis in children below the age 
of 17 years in Switzerland (Supplementary Table 1). The ten study centers host all tertiary 
neonatal intensive care units (NICU) of the country and comprise all tertiary pediatric oncology 
and pediatric surgery services. 
We obtained written informed consent from patients, or their legal guardians before study 
enrollment. In patients who fulfilled inclusion criteria but consent was not available, waiver from 
informed consent had been granted by the ethics commission for collection of anonymized 
clinical data. The study was approved by the ethics committees of all participating centers 
(Cantonal Ethics Committee, Inselspital, University of Bern, no. KEK- 029/11). 
Study population and Definitions 
All neonates and children <17 years of age with blood culture-proven invasive bacterial or fungal 
infection and SIRS, as defined by 2005 consensus definitions,
2
 were eligible if they met SIRS 
criteria at the time of blood culture sampling. Blood cultures were processed according to the 
standard operating procedures of the local microbiological laboratories. At each study site, the 
clinician in charge of patient enrollment was notified by the microbiology laboratory using an 
automated alert process. We excluded children if blood culture isolates were considered to be 
contaminants (Supplementary Methods). Additionally, we excluded children after allogeneic 
bone marrow transplantation. SIRS criteria were assessed prospectively by clinicians. Data on 
demographics, perinatal and other risk factors, comorbidities, infection site, severity, and 
outcome were entered prospectively into an online database. Data monitoring and quality controls 
were performed by the local Clinical Trial Units under the guidance of SwissPedNet, a 
coordination platform for pediatric clinical research in Switzerland and member of the Swiss 
Clinical Trial Organization (www.scto.ch). We defined organ dysfunctions (cardiovascular, 
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respiratory, hepatic, renal, neurologic, hematologic) according to the 2005 consensus definitions;
2 
organ dysfunctions were recorded from the time of blood culture sampling on. 30-day in-hospital 
mortality was the primary outcome. We defined a priori three patient groups: i) Previously 
healthy children, including term born infants ≥28 days of age; ii) Neonates, including term born 
neonates <28 days of age and prematurely born neonates <44 weeks postconceptional age at 
sepsis onset; and iii) Children ≥28 days of age with comorbidities, such as chronic inborn or 
acquired medical conditions, recent surgery or burns. Comorbidities were categorized according 
to the pediatric complex chronic conditions classification system version 2.
16
 Hospital-acquired 
infection (i.e., blood culture obtained > 48h after admission) and central line-associated 
bloodstream infection (CLABSI) were defined according to the CDC criteria.
17
Incidence calculation 
To calculate incidence rates of blood culture-proven bacterial sepsis, we included only sepsis 
episodes recorded in full study years, between January 1, 2012, and December 31, 2015 
(n=1126). To calculate age-specific incidence rates, we divided the number of annual sepsis 
episodes in the study by the end of year resident population in Switzerland in the respective age 
groups. Incidence rates were calculated for different age groups and age-standardized to the 
European standard population.
18
 We estimated national incidence rates of blood culture-proven 
bacterial sepsis based on mandatory hospital statistics of Swiss children <17 years with an ICD-
10 code for sepsis associated to a specific pathogen (Supplementary Methods and Supplementary 
Table 1). 
Statistics 
Descriptive statistics are presented as median and interquartile ranges (IQR) for continuous 
variables and frequencies and percentages for categorical variables. We used 𝜒2 test of 
proportions and the Wilcoxon non-parametric rank sum test to compare covariates between 
children >28days with one or multiple comorbidities. Post-hoc Bonferroni correction was 
applied. 
We fitted multilevel binomial regression models for potential determinants (patient group, 
number of organ dysfunctions, and gender) of death within the first 30 days after sepsis onset 
with the presence of organ dysfunctions using a random effect to correct for correlation between 
multiple observations at the same hospital. For this analysis we included only the first sepsis 
episode of each patient (n=1096), to avoid conditionality between repeat sepsis events in the 
same patient. We separately fitted univariable models for the patient group, the number of organ 
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dysfunctions present (such as any organ dysfunction, two and more organ dysfunctions, three and 
more organ dysfunctions), and gender. Then we fitted multivariable (adjusted) models containing 
all potential risk factors. We used backward stepwise selection with likelihood ratio tests to 
eliminate covariates with p>0.1 from the adjusted models. The best fitted model included the 
patient group and the presence of any organ dysfunction, two and more organ dysfunctions, four 
and more organ dysfunctions, and six organ dysfunctions. Due to the low number of observations 
with more than 4 organ dysfunctions, in the final selected model we adjusted for patient group 
and organ dysfunctions, categorized into no organ dysfunction, one organ dysfunction, two or 
three organ dysfunctions, and four or more organ dysfunctions. Corresponding area under the 
receiver operating characteristic curve (AUROC) was used to evaluate the performance of the 
model in assessing the risk for 30-day in-hospital mortality. Results of binomial multilevel 
regression analysis are presented as odds ratio (OR) with 95% confidence interval (CI) and p-
value. We considered a 2-sided p-value of <0·05 as significant. All analyses and plots were done 
using R version 3.4.0 (R Core Team (2016). R: A language and environment for statistical 
computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-
project.org/). 
Role of the funding source 
The sponsor of the study had no role in the study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding authors had full access to all the data in 
the study and had final responsibility for the decision to submit for publication. 
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Results 
We prospectively recorded 1204 eligible blood culture-proven sepsis episodes in 1110 children 
during the 52 months of the study (Figure 1). Twenty-three (2%) episodes with fungal septicemia 
were excluded for this analysis. Of the remaining 1181 blood culture-proven bacterial sepsis 
episodes, 382 (32%) occurred in previously healthy children, 402 (34%) in neonates, and 397 
(34%) in children with comorbidities (Table 1). Seventy-nine (7%) children experienced two or 
more sepsis episodes (median 2, range 2-7). 
Incidence 
The crude annual incidence of blood culture-proven bacterial sepsis per 100'000 children was 
19·1 (95%-CI 18·0-20·3), corresponding to an age-standardized incidence of 20·1 per 100'000 
children (95%-CI 18·9-21·2). The estimated national age-standardized incidence of blood 
culture-proven bacterial sepsis was 25·1 per 100'000 children per year (95%-CI 23·8-26·4). The 
national incidence of blood culture-proven bacterial sepsis was strongly age-dependent, with 
highest estimates in neonates (146·0 per 100'000 neonates; 95%-CI 133·2-159·6), and infants 
(85·3 per 100'000 infants; 95%-CI 75·6-95·9) (Figure 2). The estimated national age-
standardized incidence of blood culture-proven bacterial sepsis with any organ dysfunction was 
8·3 per 100'000 children per year (95%-CI 7·5-9·1) (Figure 2). 
Site of infection and pathogens 
CLABSI and primary bloodstream infection were the most frequent sites of infection in the entire 
cohort (327/1181, 28% and 242/1181, 20%, respectively), in neonates (125/402, 31% and 
146/402, 36%, respectively), and in children with comorbidities (202/397, 51% and 47/397, 12%, 
respectively) (Table 2). CLABSI-associated sepsis was primarily hospital-acquired (227/327, 
69%). A distinct site of infection was identified in 333/382 (87%) previously healthy children 
(Table 2), frequently associated to a particular pathogen (Supplementary Figure S1). 
E. coli (242/1181, 20%), S. aureus (177/1181, 15%), coagulase negative staphylococci
(135/1181, 11%), and S. pneumoniae (118/1181, 10%) were the most prevalent pathogens in our 
study, accounting for 57% of episodes (Table 2). The distribution of infection sites and pathogens 
showed major differences pertinent to the three patient groups and age (Figure 3). 
In 36/1181 (3%) episodes multi-resistant bacteria were cultured, including extended-spectrum 
beta-lactamase resistant bacteria in 23/1181 (2%), methicillin-resistant S. aureus in 8/1181 (1%), 
and carbapenemase resistant bacteria in 5/1181 (0%). 
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Severity and outcome of sepsis 
In 570/1181 (48%) episodes, children were treated in PICU or NICU, including 271/1181 (23%) 
episodes were children required intensive care admission because of blood culture-proven 
bacterial sepsis (Table 3). In 455/1181 (39%) episodes an organ dysfunction was present. 
Respiratory dysfunction (348/1181, 29%) and cardiovascular dysfunction (215/1181, 18%) were 
the most prevalent organ dysfunctions recorded (Supplementary Table S2), with inotropes 
required in 177/1181 (15%) episodes and new invasive ventilation required in 201/1181 (17%) 
episodes (Table 3). 
Eighty-two children died within the first 30 days after the time of blood culture sampling, 
resulting in a case fatality ratio (CFR) of 7% (95%-CI 5·6-8·6) with a median time to death of 2 
days (IQR 1-7) (Table 3). The CFR was lower in previously healthy children (10/382, 3% (95%-
CI 1·3-4·9)) than in neonates (45/402, 11% (95%-CI 8·4-14·8)) and in children with 
comorbidities (27/397, 7% (95%-CI 4·6-9·9)) (Table 3). This was confirmed in regression 
analysis with an adjusted OR for death in neonates of 4·41 (95%-CI 1·75-11·1) and 4·97 (95%-
CI 1·84-13·4)) in children with comorbidities compared to previously healthy children (Table 4 
and Supplementary Table S3). In children with comorbidities, those with multiple comorbidities 
were more often treated in PICU than children with a single comorbidity (57/103, 55% vs. 
82/294, 28%, p < 0·0001), more often required respiratory support (35/103, 34% vs. 35/294, 
12%, p < 0·0001), and inotropes (29/103, 28% vs. 36/294, 12%, p = 0·005), and had a longer 
length of stay after sepsis onset (20 days (IQR 12-57) vs. 13 days (IQR 7-24), p = 0·0009), while 
the CFR was not different (10/103, 10% vs. 17/294, 6%, p = 1·0) (Supplementary Table S4). 
The CFR was lower in children with no organ dysfunction (5/726, 1% (95%-CI 0·3-1·7)) 
compared to those with at least one organ dysfunction (77/455, 17% (95%-CI 13·7-20·8)). The 
CFR increased with rising number of organ dysfunctions present (Figure 4, Supplementary Table 
S2, and Supplementary Figure S2). 
In adjusted regression analyses, the CFR increased in the presence of one (OR 4·97 (95%-CI 
1·43-17·2)), two or three (OR 49·5 (95%-CI 16·1-152)), and four or more organ dysfunctions 
(OR 275 (95%-CI 78·6-962)) (Table 4 and Supplementary Table S3). The model performed well 
to identify children with fatal outcome (AUROC 0·92, 95%-CI 0·89-0·92). 
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Discussion 
In this prospective, population-based study in a high-income country, the age-standardized 
incidence of pediatric blood culture-proven bacterial sepsis, as defined by 2005 consensus 
criteria,
2
 was 25·1 per 100'000 children per year with an average 30-day in-hospital mortality of 
7% (95%-CI 5·6-8·6). We observed major differences in clinical presentation, causative 
pathogen, disease severity, and outcome of sepsis between previously healthy children, neonates, 
and children with comorbidities. While the majority of blood culture-proven bacterial sepsis 
episodes had no organ dysfunction which was associated with a CFR of <1%, presence and 
number of organ dysfunctions strongly increased 30-day in-hospital mortality. 
To the best of our knowledge, this is the largest population-based prospective study capturing 
blood culture-proven bacterial sepsis in all neonatal and pediatric age groups with detailed 
characterization of clinical host phenotypes. Our study fills an important knowledge gap, given 
that the majority of previous studies on sepsis in children included up to 50% of patients with 
suspected infections, lacking comprehensive microbiological diagnostics or including 
microbiological results that may represent colonization or viral infection.
19,20
 In comparison, 
pathogen-specific sepsis, as captured by our study, accounted for 66% (1190/1813) of pediatric 
hospital admissions coded as sepsis in 2012-2015 in the ten study centers, in comparison to 56% 
(1534/2736) when assessing all pediatric hospital admissions in Switzerland using ICD-10 
discharge coding (Supplementary Table 1). In agreement with a US and European study on 
bloodstream infections in adults,
5
 our findings indicate that confirmed blood culture-proven 
bacterial sepsis represents a more severe infection phenotype, associated with significantly higher 
mortality compared to other studies based on clinical definitions of sepsis.
19
Based on our data, 4% (95%-CI 3·5-5·4) of all childhood deaths in the years 2012 to 2015 in 
Switzerland
21
 were associated with blood culture-proven bacterial sepsis, with blood culture-
proven bacterial sepsis ranking 5th of all childhood death causes. This is lower than reported in 
previous studies in Finland,
22
 a country with a very low childhood mortality, and Wales,
23 
however, these were based on coding for any infectious cause using death registrations. 
While bloodstream infections are likely to be underreported in hospital coding-based reports as 
patients may be coded according to the underlying focus of infection, our study was based on 
prospective screening by pediatric infectious disease teams and automated microbiology 
laboratory reporting. 
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Our study demonstrates the importance of organ dysfunction to identify patient groups at 
substantially higher mortality risk, which can inform the translation of Sepsis-3
13
 into future 
pediatric sepsis definitions. The current definition for pediatric sepsis and sepsis severity is based 
on the 2005 consensus statement, requiring the presence of suspected infection and SIRS
2
. 
Approximately two-thirds (61%, 95%-CI (58·6-64·2)) of bacteremia episodes in our cohort were 
classified as sepsis, despite the absence of organ failure, with close to zero mortality. Presence of 
SIRS in these cases may indeed represent an appropriate rather than dysregulated host response 
to infection.
14
 In contrast, the recent Sepsis-3 consensus definition in adults discriminates sepsis 
from uncomplicated infection by the presence of organ dysfunction.
13
 Our findings demonstrate 
that the majority of pediatric invasive bacterial infections respond to appropriate antimicrobial 
treatment without the development of organ dysfunction, confirming that timely recognition of 
infection and initiation of antibiotics remain the most important cornerstones of treatment.
24
 In 
contrast, in approximately a third (39%, 95%-CI (35·8-41·4)) of sepsis episodes in our study new 
or worsening organ failure was present, associated with a dramatic increase in mortality to 17% 
(95%-CI 13·7-20·8) if at least one organ dysfunction was present, to 29% (95%-CI 22·9-34·9) if 
two or more organ dysfunctions were present. Our findings are supported by a recent 
international pediatric point prevalence study including 567 children with severe sepsis in 128 
PICUs, which reported a mortality increase from 10% in children with single organ dysfunction 
to 28% in children with new multiple organ dysfunction syndrome, and a concomitant threefold 
increase in moderate to severe disability in survivors.
25
 Importantly, while the 2005 consensus 
definitions
2
 weighted cardiovascular failure higher than other organ dysfunctions (Supplementary 
Figure S3), our findings indicate that substantial mortality increase is seen in all types of organ 
failure. Future studies should investigate mechanisms, predictors, and markers to early identify 
which children are at risk for severe organ dysfunction as a result of dysregulated host response. 
In agreement with previous reports,
7,8
 we observed that 57% of blood culture-proven bacterial 
sepsis deaths occurred within 48 hours of presentation, which has important implications for the 
design of interventional studies attempting to reduce sepsis mortality in children. 
Our study provides insight into prevailing patterns and organisms for community-acquired and 
hospital-acquired sepsis. The incidence of sepsis in our study was highest in neonates, with 
approximately 1 per 1000 developing blood culture-proven bacterial sepsis. 54% of all sepsis 
episodes in our study occurred in neonates and infants, and 74% in children below five years of 
age, likely mirroring the maturation of the innate and adaptive immune system during the first 
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years of life. Despite the decline in invasive pneumococcal infections since the introduction of 
pneumococcal vaccination in Switzerland in 2006, the majority of sepsis cases in previously 
healthy children were caused by S. pneumoniae. Of note, few sepsis cases were due to N. 
meningitidis, in contrast to other cohorts where N. meningitidis was one of the most predominant 
organisms. S. aureus was the second most common pathogen for community-acquired sepsis in 
previously healthy children, with an estimated age-standardized incidence of 3·7 per 100’000 
(95%-CI 3·2 – 4·2). In comparison, the recent Australian New Zealand Cooperative on Outcomes 
in Staphylococcal Sepsis study reported an incidence of 8·3 per 100 000 population with a 
mortality of 4·7%.
26
Approximately one-third of all blood culture-proven bacterial sepsis episodes in our study 
occurred in previously healthy children, frequently presenting with age-specific combinations of 
pathogens and sites of infection. The associated severity in previously healthy children was 
considerable, as 28% required PICU admission with a CFR of 8% (95%-CI 4%-16%). 
Underlying unrecognized primary immunodeficiencies, and other genetic and non-genetic host 
factors conferring increased susceptibility to fulminant sepsis have been shown to account for a 
proportion of severe infections in previously healthy children, but further studies are needed to 
elucidate the underlying host and pathogen interactions.
27,28
 In addition our results indicate an
urgent need for improved preventive strategies, including measures against E. coli and S. aureus 
infections which are responsible for an increasing proportion of sepsis cases given the decline in 
vaccine-preventable infections. In contrast, the majority of blood culture-proven bacterial sepsis 
episodes in neonates and children with comorbidities in our study were hospital-acquired or 
health-care associated, with CLABSI accounting for 53% of hospital-acquired sepsis. This is of 
particular relevance as most healthcare-associated infections have to be considered in principle 
preventable,
29
 indicating an urgent need for improved bundle implementation, bundle 
maintenance, and benchmarking.
30
Several limitations of this study have to be considered. First, while we included all the main 
pediatric hospitals in Switzerland, including all PICUs, NICUs, tertiary pediatric surgery, and 
oncology centers to estimate the population-based burden of disease, this may have led to a bias 
towards sepsis of greater severity, and sepsis in children with comorbidities, such as premature 
neonates and oncology patients. Second, geography, demography, epidemiology, and the 
organization of the healthcare system in Switzerland have to be considered, when attempting to 
generalize our findings. Third, we did not prospectively collect daily data on Sequential Organ 
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Failure Assessment Scores,
13
 which have not been validated for children, and the timing of 
progression towards organ failure was not assessed. Fourth, the inclusion criteria required 
presence of blood-culture-proven sepsis as per 2005 consensus criteria,
2
 and the study was 
therefore not designed to analyze contaminations and blood culture-proven infection in children 
without SIRS. Fifth, we defined 30-day mortality as main outcome, whereas longterm 
neurodevelopmental outcome and quality of health in sepsis survivors were not assessed. Sixth, 
our study excluded allogeneic bone marrow transplants which may have led to an 
underestimation of the incidence. Finally, despite the size of the study, the number of deaths was 
relatively low, limiting more extensive subgroup analyses when adjusting statistical models for 
potential covariates. 
In conclusion, this contemporary population-based cohort on pediatric blood culture-proven 
bacterial sepsis observed an ongoing burden of disease in a high-income country. The findings 
demonstrate distinct patterns in relation to epidemiology, host susceptibility, pathogen spectrum, 
and outcomes of pediatric sepsis. While the majority of bacteremia episodes had no organ 
dysfunction with close to zero mortality, we demonstrated the importance of organ dysfunction to 
characterize patients with substantially worse outcomes, which should be considered when 
reviewing pediatric sepsis definitions. These data may serve to inform current antimicrobial 
strategies and future sepsis trials and to identify high-risk populations most likely to benefit from 
targeted preventive and therapeutic interventions. 
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Panel: Research in context 
Evidence before this study: We searched PubMed for studies published in English, reporting 
longitudinal population-based data for incidence and mortality of bacteremia and sepsis in 
children <17 years published between 1990 and 2016. We used the search terms “bacteremia”, 
“blood culture”, “bloodstream infection”, “mortality”, “sepsis”, “child”, and “epidemiology”. 
Invasive bacterial infections represent one of the leading causes of childhood mortality 
worldwide, and contribute to 11 - 20% of childhood deaths in high-income countries. The 
incidence of invasive infections is highest in neonates and children, yet there is a lack of 
population-based analyses on microbiologically confirmed severe bacterial infections in 
childhood. In addition to age, host factors such as underlying disease are primary determinants of 
susceptibility and outcomes. A limitation of larger studies on childhood sepsis consists in the use 
of clinical definitions of sepsis, with only a minority of sepsis episodes being microbiologically 
confirmed, and lack of robust characterization of comorbidities. Considering the detrimental 
effect of delays in antimicrobial treatment in bacterial sepsis, representative data on the 
contemporary burden of bacterial sepsis are urgently needed to guide national strategies for 
optimal antibiotic usage. Added value: We report specific patterns of clinical presentation, 
causative pathogen, disease severity, and outcome of sepsis which differed significantly between 
previously healthy children, neonates, and children with comorbidities. While the majority of 
bacteremia episodes had no organ dysfunction with close to zero mortality, presence and number 
of organ dysfunctions were strongly associated with mortality. Implications of all the available 
evidence: We demonstrate an ongoing high burden of pediatric bacterial sepsis and identify high-
risk groups most likely to benefit from targeted preventive and therapeutic interventions, which 
can inform current management strategies and future sepsis trials, in particular in view of the next 
iteration of pediatric Surviving Sepsis Guidelines and pediatric-specific sepsis definitions. 
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Tables 
Table 1 - Demographic and clinical characteristics of neonates and children 
with blood culture-proven bacterial sepsis 
All episodes 
(n = 1181, in 1096 
children) 
Episodes in 
previously healthy 
children 
(n = 382, in 379 
children) 
Episodes in 
neonates 
(n = 402, in 391 
infants) 
Episodes in 
children with 
comorbidities 
(n = 397, in 341 
children) 
Demographics 
Age at sepsis onset (months) 7·6 (0·6-63·6) 44·3 (6-108·2) 0·3 (0·2-0·7) 37·4 (9·7-98·7) 
Age groups 
Preterm newborn <44 weeks 
postconceptional age 266 (22·5%) 266 (66·2%) 
Term newborn <28 days 136 (11·5%) 136 (33·8%) 
28-365 days 237 (20·1%) 126 (33·0%) 111 (28·0%) 
1-4 years 235 (19·9%) 96 (25·1%) 139 (35·0%) 
5-9 years 148 (12·5%) 76 (19·9%) 72 (18·1%) 
10-16 years 159 (13·5%) 84 (22·0%) 75 (18·9%) 
Male 705 (59·7%) 220 (57·6%) 254 (63·2%) 231 (58·2%) 
Ethnicity
a
 
Caucasian 915 (85·1%) 300 (89·6%) 313 (87·2%) 302 (79·3%) 
Asian 39 (3·6%) 12 (3·6%) 6 (1·7%) 21 (5·5%) 
African 49 (4·6%) 13 (3·9%) 9 (2·5%) 27 (7·1%) 
other 72 (6·7%) 10 (3·0%) 9 (2·5%) 31 (8·1%) 
Clinical characteristics 
Comorbidities
b
 
Neurologic and 
neuromuscular 41 (3·5%) 10 (2·5%) 31 (7·8%) 
Cardiovascular 90 (7·6%) 20 (5·0%) 70 (17·6%) 
Respiratory 56 (4·7%) 16 (4·0%) 40 (10·1%) 
Renal and urologic 46 (3·9%) 8 (2·0%) 38 (9·6%) 
Gastrointestinal 92 (7·8%) 17 (4·2%) 75 (18·9%) 
Haematologic or 
Immunologic 18 (1·5%) 0 (0%) 18 (4·5%) 
Metabolic 18 (1·5%) 5 (1·2%) 13 (3·3%) 
Other congenital or genetic 
defect 39 (3·3%) 14 (3·5%) 25 (6·3%) 
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Malignancy 144 (12·2%) 0 (0%) 144 (36·3%) 
Neonatal
c
 209 (17·7%) 209 (52·0%) 0 (0%) 
Surgery or burn 86 (7·3%) 28 (7·0%) 58 (14·6%) 
Technology dependence
d
 42 (3·6%) 26 (6·5%) 16 (4·0%) 
Solid organ transplantation 17 (1·4%) 0 (0%) 17 (4·3%) 
> 1 condition 159 (13·5%) 56 (13·9%) 103 (25·9%) 
Hospital acquired sepsis 431 (36·5%) 16 (4·2%) 243 (60·4%) 172 (43·3%) 
CVAD present at time of 
sepsis onset 452 (38·3%) 176 (43·8%) 276 (69·5%) 
Length of stay after sepsis 
onset
e
 (days) 13 (8-29) 9 (5-13) 21 (12-65) 14 (8-29) 
Antibiotic therapy 
Adequate empiric antibiotic 
treatment
f
 1020 (86·4%) 350 (91·6%) 343 (85·5%) 327 (82·4%) 
Length of antibiotic 
treatment
g
 (days) 14 (10-15) 14 (10-21) 11 (8-14) 14 (10-15) 
CVAD=central venous access device 
Categorical variables are given as frequencies and percentages, continuous variables as median 
and interquartile range. Column percentages are given. Percentages are based upon available data 
for each variable. 
a
data not available in 106. 
b
More than one comorbidity may be present in a child, numbers and
percentages do not add up. 
c
Gestational age <27 weeks, birthweight <750g, history of mechanical
ventilation, history of necrotizing colitis. 
d
Central line, or urinary catheter, or ventriculo-
peritoneal shunt system present at sepsis onset, or total parental nutrition in a child that does not 
have any other comorbidity. 
e
data not available in 11 episodes (discharge to another facility; still
hospitalized). 
f
data not available in 1 episode (child died before receiving antibiotic treatment).
g
data not available in 4 episodes. 
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Table 2 - Site of infection and pathogens identified in neonates and children 
with blood culture-proven bacterial sepsis 
All episodes 
(n = 1181, in 
1096 children) 
Episodes in 
previously healthy 
children 
(n = 382, in 379 
children) 
Episodes in 
neonates 
(n = 402, in 391 
infants) 
Episodes in 
children with 
comorbidities 
(n = 397, in 341 
children) 
Site of infection 
Primary bloodstream infection 242 (20·5%) 49 (12·8%) 146 (36·3%) 47 (11·8%) 
Central line-associated 
bloodstream infection 327 (27·7%) 0 (0%) 125 (31·1%) 202 (50·9%) 
Urinary tract infection 128 (10·8%) 56 (14·7%) 35 (8·7%) 37 (9·3%) 
Pneumonia 112 (9·5%) 76 (19·9%) 22 (5·5%) 14 (3·5%) 
Central nervous system 
infection 85 (7·2%) 53 (13·9%) 25 (6·2%) 7 (1·8%) 
Bone and joint infection 68 (5·8%) 59 (15·4%) 4 (1·0%) 5 (1·3%) 
Gastrointestinal system 
infection 72 (6·1%) 18 (4·7%) 22 (5·5%) 32 (8·1%) 
Skin and soft tissue infection 51 (4·3%) 25 (6·5%) 12 (3·0%) 14 (3·5%) 
Surgical site infection 17 (1·4%) 1 (0·3%) 4 (1·0%) 12 (3·0%) 
Ear, Nose, and Throat infection 29 (2·5%) 23 (6·0%) 4 (1·0%) 2 (0·5%) 
Cardiovascular system 
infection 10 (0·8%) 1 (0·3%) 1 (0·2%) 8 (2·0%) 
Toxic shock Syndrome 8 (0·7%) 6 (1·6%) 0 (0%) 2 (0·5%) 
Other specific infection type 32 (2·7%) 15 (3·9%) 2 (0·5%) 15 (3·8%) 
Pathogens 
Gram positive bacteria 729 (61·7%) 260 (68·1%) 261 (64·9%) 208 (52·4%) 
S. aureus 177 (15·0%) 66 (17·3%) 48 (11·9%) 63 (15·9%) 
Coagulase negative 
staphylococci 135 (11·4%) 0 (0%) 86 (21·4%) 49 (12·3%) 
S. pneumoniae 118 (10·0%) 90 (23·6%) 4 (1·0%) 24 (6·0%) 
Viridans group streptococci 59 (5·0%) 15 (3·9%) 9 (2·2%) 35 (8·8%) 
Group A streptococci 53 (4·5%) 47 (12·3%) 3 (0·7%) 3 (0·8%) 
Group B streptococci 105 (8·9%) 24 (6·3%) 79 (19·7%) 2 (0·5%) 
Enterococcus species 42 (3·6%) 6 (1·6%) 16 (4·0%) 20 (5·0%) 
Other Gram positive bacteria 40 (3·4%) 12 (3·1%) 16 (4·0%) 12 (3·0%) 
Gram negative bacteria 452 (38·3%) 122 (31·9%) 141 (35·1%) 189 (47·6%) 
E.coli 242 (20·5%) 62 (16·2%) 96 (23·9%) 84 (21·2%) 
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H. influenzae 21 (1·8%) 17 (4·5%) 1 (0·2%) 3 (0·8%) 
Klebsiella species 55 (4·7%) 0 (0%) 20 (5·0%) 35 (8·8%) 
N. meningitidis 28 (2·4%) 26 (6·8%) 0 (0%) 2 (0·5%) 
P. aeruginosa 24 (2·0%) 2 (0·5%) 4 (1·0%) 18 (4·5%) 
Other Gram negative bacteria 82 (6·9%) 15 (3·9%) 20 (5·0%) 47 (11·8%) 
Data are n (%). Column percentages are given. 
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Table 3 - Severity of sepsis episodes in neonates and children with blood 
culture-proven bacterial sepsis 
All episodes 
(n = 1181, in 
1096 children) 
Episodes in 
previously 
healthy children 
(n = 382, in 379 
children) 
Episodes in 
neonates 
(n = 402, in 391 
infants) 
Episodes in 
children with 
comorbidities 
(n = 397, in 341 
children) 
Organ dysfunctions 
No organ dysfunction present 726 (61·5%) 281 (73·6%) 174 (43·3%) 271 (68·3%) 
1 organ dysfunction 224 (19·0%) 43 (11·3%) 132 (32·8%) 49 (12·3%) 
2 organ dysfunctions 111 (9·4%) 25 (6·5%) 51 (12·7%) 35 (8·8%) 
3 organ dysfunctions 56 (4·7%) 9 (2·4%) 23 (5·7%) 24 (6·0%) 
4 organ dysfunctions 30 (2·5%) 9 (2·4%) 14 (3·5%) 7 (1·8%) 
5 organ dysfunctions 20 (1·7%) 10 (2·6%) 5 (1·2%) 5 (1·3%) 
6 organ dysfunctions 14 (1·2%) 5 (1·3%) 3 (0·7%) 6 (1·5%) 
PICU/ NICU admission
a
 570 (48·3%) 108 (28·3%) 323 (80·3%) 139 (35·0%) 
PICU/ NICU admission due to 
sepsis 271 (23·0%) 103 (27·0%) 100 (24·9%) 68 (17·1%) 
Length of PICU stay
b
 (days) 14 (4-52) 4 (2-9) 25 (8-66) 14 (3-68) 
Length of PICU stay due to 
sepsis
c
 (days) 4 (2-11) 4 (2-9) 6 (4-17) 3 (1-9) 
Invasive ventilation
a
 307 (26·0%) 54 (14·2%) 183 (45·5%) 70 (17·6%) 
Invasive ventilation due to sepsis 201 (17·0%) 51 (13·4%) 109 (27·1%) 41 (10·3%) 
Non-invasive ventilation 178 (15·1%) 17 (4·5%) 141 (35·1%) 20 (5·0%) 
Non-invasive ventilation due to 
sepsis 70 (5·9%) 14 (3·7%) 50 (12·4%) 6 (1·5%) 
Inotrope requirement
a
 177 (15·0%) 46 (12·0%) 66 (16·4%) 65 (16·4%) 
Case fatality 82 (6·9%) 10 (2·6%) 45 (11·2%) 27 (6·8%) 
Time to death from sepsis onset 
(days) 2 (1-7) 2 (0-2) 1 (1-5) 6 (1-16) 
PICU=pediatric intensive care unit. NICU=neonatal intensive care unit. 
Categorical variables are given as frequencies and percentages, continuous variables as median 
and interquartile range. Column percentages are given. Percentages are based upon available data 
for each variable. 
a
data not available in 1 episode. 
b
data not available in 31 episodes. 
c
data not available in 14
episodes. 
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Table 4: Risk factors for death in neonates and children with blood culture-proven bacterial sepsis 
sepsis episodes in which 
children survived 
sepsis episodes in 
which children died Unadjusted model Adjusted model 
n = 1023 n = 73 OR (95% CI) p value
b
 OR (95% CI) p value
b
 
Patient group 0·0003 0·0007 
Previously healthy children
a
, n=375 366 (97·6%) 9 (2·4%) 
Neonates, n=391 349 (89·3%) 42 (10·7%) 4·19 (1·94-9·04) 4·41 (1·75-11·1) 
Children with comorbidities, n=330 308 (93·3%) 22 (6·7%) 2·86 (1·28-6·40) 4·97 (1·84-13·4) 
Number of organ dysfunctions <0·0001 <0·0001 
No organ dysfunction
a
, n=671 667 (99·4%) 4 (0·6%) 
1 organ dysfunction, n=207 198 (95·7%) 9 (4·3%) 5·78 (1·68-19·9) 4·97 (1·43-17·2) 
2 or 3 organ dysfunctions, n=160 127 (79·4%) 33 (20·6%) 56·7 (18·6-173) 49·5 (16·1-152) 
4 to 6 organ dysfunctions, n=58 31 (53·4%) 27 (46·6%) 212 (64·0-704) 275 (78·6-962) 
OR=odds ratio. CI=confidence interval. Data are n (%) unless otherwise specified. Row percentages are given. 
Unadjusted and adjusted OR for death investigating potential risk factors patient group and number of organ dysfunctions in multilevel 
binomial regression. The adjusted model was adjusted for all variables listed. Outcome was death within the first 30 days after sepsis 
onset (yes/no). 
a
reference category. 
b
p value from likelihood ratio test
1272 sepsis episodes in 1170 
children included by investigators
68 (5·3%) episodes
- 11 episodes considered ineligible by
investigators
- 12 episodes with no organism isolated
in blood culture
- 45 episodes with coagulase negative
staphylococcus isolated in patients with
no central venous line
1204 episodes in 1110 children 
eligible for analysis
23 (1·9%) episodes with isolation of a fungal 
pathogen in blood culture excluded for this 
analysis
1181 episodes in 1096 children 
analysed
382 (32%) episodes in 379 
previously healthy children
281 (74%) 
episodes 
without organ 
dysfunction
No (0%) 
episode with 
fatal outcome
101 (26%) 
episodes with 
organ 
dysfunction
10 (9·9%) 
episodes with 
fatal outcome
402 (34%) episodes in 391 
neonates
174 (43%) 
episodes 
without organ 
dysfunction
1 (0·6%) 
episode with 
fatal outcome
228 (57%)
episodes with 
organ 
dysfunction
44 (19%) 
episodes with 
fatal outcome
397 (34%) episodes in 341 
children with comorbidities
271 (68%) 
episodes 
without organ 
dysfunction
4 (1·5%) 
episodes with 
fatal outcome
126 (32%) 
episodes with 
organ 
dysfunction
23 (18%) 
episodes with 
fatal outcome
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Figures 
Figure 1: Flow chart of sepsis episodes included in the Swiss Pediatric Sepsis Study 
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Figure 2: Incidence of blood culture-proven bacterial sepsis in the years 2012-2015 in 
Switzerland, grouped by age. 
Red horizontal lines show the crude incidence (n=1126), as measured in the ten participating study 
centers, black horizontal lines the estimated national incidence of all blood culture-proven bacterial sepsis 
in Switzerland (Panel A), and blood culture-proven bacterial sepsis with organ dysfunction (n=439) (Panel 
B). The estimate of national sepsis incidence is based on the assumption that participating hospitals 
captured 80% of all sepsis episodes in children up to 16 years in Switzerland and 90% of all episodes with 
organ dysfunction (irrespective of age). Vertical lines represent the 95% confidence intervals around the 
point estimates for each age group. 
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Figure 3: Age distribution of sites of infection and responsible pathogens causing blood culture-proven bacterial sepsis in 
children. 
Sites of infection are shown for the three patient groups (A) and separately for previously healthy children ≥28 days of age (B), and for neonates, and 
children with comorbidities ≥28 days of age (C) grouped by age. Pathogens isolated in blood culture are shown for the three patient groups (D), and 
separately for previously healthy children ≥28 days of age (E), and for neonates, and children with comorbidities ≥28 days of age (F) grouped by age. 
CLABSI=central line-associated bloodstream infection. CoNS=coagulase negative staphylococci. 
a
Skin infection, wound infection, endocarditis, toxic 
shock syndrome, ear-nose-throat infection, other non-specified focal infection. 
b
P. aeruginosa, Klebsiella spp., N. meningitidis, H. influenzae, other 
Gram-negative pathogens. 
c
Enterococcus spp., viridans group streptococci, other Gram-positive pathogens
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Figure 4: Impact of organ dysfunction on case fatality ratio in children with sepsis. 
Horizontal lines represent point estimates of the case fatality ratio in children with sepsis stratified by 
number of organ dysfunctions present. Vertical lines represent the 95% confidence intervals around the 
point estimates for each group. 
